| 摘要 |
The present invention relates to a pharmaceutical composition comprising, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of said mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. |
